[1]
Alzforum newsletter March 25, 2019: https://www.alzforum.org/news/research-news/biogeneisai-halt-phase-3-aducanumab-trials
[2]
Hsu D, Marshall GA. Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward. Curr Alzheimer Res 14(4): 426-40. (2017).
[3]
Maloney B, Lahiri DK. Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol 15(7): 760-74. (2016).
[4]
Weinstein G, Preis SR, Beiser AS, Kaess B, Chen TC, Satizabal C, et al. Clinical and environmental correlates of serum BDNF: A descriptive study with plausible implications for AD research. Curr Alzheimer Res 14(7): 722-30. (2017).
[5]
Lauritzen I, Pardossi-Piquard R, Bourgeois A, Bécot A, Checler F. Does intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s disease? Curr Alzheimer Res (2019).
[http://dx.doi.org/10.2174/1567205016666190325092841]
[http://dx.doi.org/10.2174/1567205016666190325092841]
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
38
8
1
1